humanized anti-PD-1 monoclonal antibody toripalimab

BIOLOGICAL6 trials

Conditions

Advanced MelanomaBladder Urothelial CarcinomaBreast CancerKidney Cancer Stage IvMetastatic MelanomaMucosal MelanomaSolid Tumors

Phase 1

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

CompletedNCT02838823

Shanghai Junshi Bioscience Co., Ltd.Breast Cancer

Start: 2016-07-31End: 2019-09-30Updated: 2019-10-23

Study of JS001 in Participants With Advanced Solid Tumors

CompletedNCT02857166

Shanghai Junshi Bioscience Co., Ltd.Solid Tumors

Start: 2016-03-31End: 2018-12-31Updated: 2019-10-23

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

NCT03086174

Shanghai Junshi Bioscience Co., Ltd.Advanced Melanoma, Kidney Cancer Stage Iv

Start: 2017-03-31End: 2020-12-31Target: 24Updated: 2020-09-30

Phase 2

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

NCT03013101

Shanghai Junshi Bioscience Co., Ltd.Advanced Melanoma, Metastatic Melanoma

Start: 2016-12-28End: 2021-12-31Updated: 2020-09-30

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

NCT03113266

Shanghai Junshi Bioscience Co., Ltd.Bladder Urothelial Carcinoma

Start: 2017-04-06End: 2022-02-28Target: 370Updated: 2020-09-30

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

TerminatedNCT03178123

Shanghai Junshi Bioscience Co., Ltd.Mucosal Melanoma

Start: 2017-05-31End: 2019-06-30Updated: 2026-07-27

Journal for ImmunoTherapy of Cancer2024-06-0115 citations

Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study.

Journal of Clinical Oncology2022-06-011 citations

Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): Two-year survival update and biomarker analysis.

Journal of Clinical Oncology2022-06-011 citations

Recombinant humanized Anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma (POLARIS-03 study): Two-year survival update and biomarker analysis.

Journal of Clinical Oncology2022-02-16

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

Journal for ImmunoTherapy of Cancer2022-02-0147 citations

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies

Frontiers in Pharmacology2021-11-092 citations

Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial.

Journal of Clinical Oncology2021-05-204 citations

Four-year survival follow-up of toripalimab (JS001) as salvage therapy in Chinese melanoma patients.

Journal of Clinical Oncology2021-05-202 citations

Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study.

Journal of Clinical Oncology2021-02-20

Abstract IA16: The landscape of mucosal melanoma: A long way to go

Cancer Research2020-10-01

Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Journal of Clinical Oncology2020-05-2012 citations

Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Results of an open-label phase II clinical study Polaris-03.

Journal of Clinical Oncology2020-05-207 citations

Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study (POLARIS-03).

Journal of Clinical Oncology2020-02-193 citations

JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial.

2019-09-0124 citations

Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.

Journal of Clinical Oncology2019-05-202 citations

Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study.

Journal of Clinical Oncology2019-05-202 citations

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.

2019-01-14127 citations

A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.

Journal of Clinical Oncology2018-05-2014 citations

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.

Journal of Clinical Oncology2018-05-2010 citations

Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.

Journal of Clinical Oncology2018-05-203 citations

1 more papers not shown

humanized anti-PD-1 monoclonal antibody toripalimab

Sponsors

Conditions

Phase 1

Phase 2

Related Papers